FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386474518> ?p ?o ?g. }

• W4386474518 endingPage "101621" @default.
• W4386474518 startingPage "101621" @default.
• W4386474518 abstract "Prostate cancer (PC) is the second commonest malignancy and fifth leading cause of cancer death in men worldwide. Older men are more likely to develop PC but are underrepresented in pivotal clinical trials, leading to challenges in treatment selection in the real-world setting. We aimed to examine treatment patterns and outcomes in older Australians with metastatic castration-resistant prostate cancer (mCRPC).We identified 753 men with mCRPC within the electronic CRPC Australian Database (ePAD). Clinical data were analysed retrospectively to assess outcomes including time to treatment failure (TTF), overall survival (OS), PSA doubling time (PSADT), PSA50 response rate, and pre-defined adverse events of special interest (AESIs). Descriptive statistics were used to report baseline characteristics, stratified by age groups (<75y, 75-85y and >85y). Groups were compared using Kruskal-Wallis and Chi-square analyses. Time-to-event analyses were performed using Kaplan-Meier methods and compared through log-rank tests. Cox proportional hazards univariate and multivariate analyses were performed to evaluate the influence of variables on OS.Fifty-seven percent of men were aged <75y, 31% 75-85y, and 12% >85y. Patients ≥75y more frequently received only one line of systemic therapy (40% of <75y vs 66% 75-85y vs 68% >85y; P < 0.01). With increasing age, patients were more likely to receive androgen receptor signalling inhibitors (ARSIs) as initial therapy (42% of <75y vs 70% of 75-85y vs 84% of >85y; p < 0.01). PSA50 response rates or TTF did not significantly differ between age groups for chemotherapy or ARSIs. Patients >85y receiving enzalutamide had poorer OS but this was not an independent prognostic variable on multivariate analysis (hazard ratio [HR] 0.93(0.09-9.35); p = 0.95). PSADT >3 months was an independent positive prognostic factor for patients receiving any systemic therapy. Older patients who received docetaxel were more likely to experience AESIs (18% in <75y vs 37% 75-85y vs 33% >85y, p = 0.038) and to stop treatment as a result (21% in <75y vs 39% in 75-85y; p = 0.011).In our mCRPC cohort, older men received fewer lines of systemic therapy and were more likely to cease docetaxel due to adverse events. However, treatment outcomes were similar in most subgroups, highlighting the importance of individualised assessment regardless of age." @default.
• W4386474518 created "2023-09-07" @default.
• W4386474518 creator A5000291176 @default.
• W4386474518 creator A5011946923 @default.
• W4386474518 creator A5012934281 @default.
• W4386474518 creator A5018801649 @default.
• W4386474518 creator A5039434057 @default.
• W4386474518 creator A5040106846 @default.
• W4386474518 creator A5040246688 @default.
• W4386474518 creator A5040654138 @default.
• W4386474518 creator A5041391031 @default.
• W4386474518 creator A5044715236 @default.
• W4386474518 creator A5055735681 @default.
• W4386474518 creator A5067802897 @default.
• W4386474518 creator A5075093609 @default.
• W4386474518 creator A5076548846 @default.
• W4386474518 creator A5077677224 @default.
• W4386474518 creator A5082697210 @default.
• W4386474518 creator A5086080884 @default.
• W4386474518 date "2023-11-01" @default.
• W4386474518 modified "2023-10-16" @default.
• W4386474518 title "Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort" @default.
• W4386474518 cites W2010362244 @default.
• W4386474518 cites W2044339366 @default.
• W4386474518 cites W2086368572 @default.
• W4386474518 cites W2099199992 @default.
• W4386474518 cites W2110534364 @default.
• W4386474518 cites W2120292596 @default.
• W4386474518 cites W2143891871 @default.
• W4386474518 cites W2145131986 @default.
• W4386474518 cites W2148643283 @default.
• W4386474518 cites W2150865892 @default.
• W4386474518 cites W2153294383 @default.
• W4386474518 cites W2168063883 @default.
• W4386474518 cites W2214621962 @default.
• W4386474518 cites W2236020469 @default.
• W4386474518 cites W2565008322 @default.
• W4386474518 cites W2620798309 @default.
• W4386474518 cites W2745577531 @default.
• W4386474518 cites W2779121547 @default.
• W4386474518 cites W2792086148 @default.
• W4386474518 cites W2810806599 @default.
• W4386474518 cites W2886632102 @default.
• W4386474518 cites W2889646458 @default.
• W4386474518 cites W2905845365 @default.
• W4386474518 cites W2913767564 @default.
• W4386474518 cites W2947893479 @default.
• W4386474518 cites W2963794755 @default.
• W4386474518 cites W3033684926 @default.
• W4386474518 cites W3083021108 @default.
• W4386474518 cites W3158318954 @default.
• W4386474518 cites W3197383983 @default.
• W4386474518 cites W3201981182 @default.
• W4386474518 cites W3209480926 @default.
• W4386474518 cites W4213196409 @default.
• W4386474518 cites W4223443163 @default.
• W4386474518 cites W4293282442 @default.
• W4386474518 cites W4293659625 @default.
• W4386474518 doi "https://doi.org/10.1016/j.jgo.2023.101621" @default.
• W4386474518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37683368" @default.
• W4386474518 hasPublicationYear "2023" @default.
• W4386474518 type Work @default.
• W4386474518 citedByCount "0" @default.
• W4386474518 crossrefType "journal-article" @default.
• W4386474518 hasAuthorship W4386474518A5000291176 @default.
• W4386474518 hasAuthorship W4386474518A5011946923 @default.
• W4386474518 hasAuthorship W4386474518A5012934281 @default.
• W4386474518 hasAuthorship W4386474518A5018801649 @default.
• W4386474518 hasAuthorship W4386474518A5039434057 @default.
• W4386474518 hasAuthorship W4386474518A5040106846 @default.
• W4386474518 hasAuthorship W4386474518A5040246688 @default.
• W4386474518 hasAuthorship W4386474518A5040654138 @default.
• W4386474518 hasAuthorship W4386474518A5041391031 @default.
• W4386474518 hasAuthorship W4386474518A5044715236 @default.
• W4386474518 hasAuthorship W4386474518A5055735681 @default.
• W4386474518 hasAuthorship W4386474518A5067802897 @default.
• W4386474518 hasAuthorship W4386474518A5075093609 @default.
• W4386474518 hasAuthorship W4386474518A5076548846 @default.
• W4386474518 hasAuthorship W4386474518A5077677224 @default.
• W4386474518 hasAuthorship W4386474518A5082697210 @default.
• W4386474518 hasAuthorship W4386474518A5086080884 @default.
• W4386474518 hasConcept C10515644 @default.
• W4386474518 hasConcept C121608353 @default.
• W4386474518 hasConcept C126322002 @default.
• W4386474518 hasConcept C143998085 @default.
• W4386474518 hasConcept C144301174 @default.
• W4386474518 hasConcept C207103383 @default.
• W4386474518 hasConcept C2777899217 @default.
• W4386474518 hasConcept C2779399171 @default.
• W4386474518 hasConcept C2780192828 @default.
• W4386474518 hasConcept C38180746 @default.
• W4386474518 hasConcept C44249647 @default.
• W4386474518 hasConcept C50382708 @default.
• W4386474518 hasConcept C66339696 @default.
• W4386474518 hasConcept C71924100 @default.
• W4386474518 hasConcept C72563966 @default.
• W4386474518 hasConceptScore W4386474518C10515644 @default.
• W4386474518 hasConceptScore W4386474518C121608353 @default.

• next